On October 1, 2024, dsm-firmenich completed the sale and transfer of its MEG-3® fish oil business, serving the Food & Beverage, Dietary Supplement, and Pharma markets. The transaction, initially announced on July 18, 2024, included the transfer of production facilities in Piura, Peru, and Mulgrave, Canada. As part of the deal, dsm-firmenich received a 29% minority stake in KD Pharma's parent company, MidCo Omega GmbH. This sale enables dsm-firmenich to streamline its focus on core sectors while KD Pharma enhances its position in the marine lipids industry.

Baker McKenzie advised KD Pharma Group, a global leader in pharmaceutical and nutritional lipids, while Clifford Chance acted as legal advisor to dsm-firmenich. Financial terms of the transaction were not disclosed.